Sixty-six untreated patients with advanced non-Hodgkin's lymphoma of favourable histological type were allocated alternately to initial treatment with cyclophosphamide, vincristine, and prednisolone or with chlorambucil. The complete remission rate was higher in the group receiving combination chemotherapy, but the overall response rate was the same for both groups. The mean duration of complete remission was the same as that of good partial remission, and was the same for both treatments. The duration of remission was influenced by histological type and extent of disease at presentation, but not age. Those who responded to the initial treatment (whether with complete or with good partial remission) survived significantly longer than did non-responders.
Introduction
Combination chemotherapy (with cyclophosphamide, vincristine, and prednisolone-CVP) has produced a significantly higher response rate in lymphosarcoma than cyclophosphamide alone.1-3 We therefore carried out a study to confirm these results (using chlorambucil instead of cyclophosphamide as the single agent) and to relate duration of remission to the initial treatment and other variables in patients with stage III and stage IV non-Hodgkin's lymphoma of favourable histological type and presumed good prognosis.
Patients and methods

PATIENTS
Sixty-seven untreated patients with stage III and IV non-Hodgkin's lymphoma were included in the study between December 1972 and May 1976 (table I). One patient was withdrawn for social reasons, leaving 66 cases for evaluation. All patients were treated at St Bartholomew's Hospital and were followed up monthly after completing the treatment.
One of us (AGS) reviewed all histological sections and the diagnosis was made according to the Rappaport classification.4 Whenever possible, imprint preparations of lymph node or other affected tissue were made and stained with a Romanowsky stain. All patients with nodular and diffuse well-differentiated lymphocytic (D-WDL) lymphoma were included. There were also 13 cases of diffuse lymphocytic lymphoma in which the cells were of intermediate differentiation.
Since Rappaport would probably have diagnosed these as diffuse poorly differentiated lymphocytic (D-PDL) lymphomas, we have designated them "diffuse poorly differentiated lymphocytic, intermediate" (D-PDL(I) ). These tumours correspond to the centrocytic lymphoma, small-cell variant, of the Kiel classification.5 No patients with D-PDL lymphoma corresponding to the large-cell variant of centrocytic lymphoma (Kiel) were included. Patients were not excluded from the study if they had leukaemia-defined as either a persistent lymphocytosis in excess of 5 x 109/l (5000/mm3) (associated with D-WDL) or the presence of abnormal peripheral blood lymphocytes identical to those in the lymph node (in patients with nodular lymphoma or D-PDL(I).
In each case the disease was staged according to the Ann Arbor classification used for Hodgkin's disease, with the following modifica- Patients were allocated alternately to receive CVP or chlorambucil alone. The two groups were of different size because we also accepted in the study patients in whom lymphocytic malignancy was diagnosed on the basis of bone marrow biopsy but who did not have a lymph node biopsy; data on these patients have not, however, been included in the analysis and will be reported later.
TREATMENT
Single agent-Oral chlorambucil, 10 mg daily, was given continuously for six weeks. After a treatment-free interval of two weeks, three 15-day courses of chlorambucil, 10 mg daily, were given with 15-day intervals between the courses. All treatment was stopped after the third course.
Combination-Six cycles of CVP were given at 21-day intervals according to the National Cancer Institute regimen3-that is, oral cyclophosphamide, 400 mg/nM2 daily, for five days; intravenous vincristine, 1 4 mg/M2 (maximum 2 mg), on the first day only; and prednisolone, 100 mg/M2 daily, for five days.
Patients on chlorambucil were examined every 14 days, and those on CVP every 21 days. Doses were adjusted or treatment was postponed for one week if the total white cell count fell below 3 x 109/l (3000/mm3) or the platelet count below 100 x 109/l (100 000/mm3). Nine patients completely failed to respond to the initial treatment. Those originally treated with chlorambucil were then given CVP and vice versa.
No patients died as a result of drug effects. All had some degree of myelosuppression,3 and everyone receiving CVP had alopecia.
No maintenance treatment was given to those who achieved remission. Relapse was treated only when it became symptomatic, unless there was histological evidence of conversion to a histological type with a poor prognosis. Most patients were treated on relapse with chlorambucil. EVALUATION We evaluated patients a month after the end of treatment stage IV disease. Lymphangiography was performed in only five of the 17 cases of complete remission. Good partial remission-Normal health associated with minimal residual disease (for example, no clinical evidence of disease but continuing focal bone marrow lesions).
Poor partial remission-Normal or reasonable health associated with more than half reduction of tumour mass.
Failure-Reasonable or poor health with less than 50 % reduction of tumour mass.
Patients who achieved complete or good partial remission were considered responders and the others non-responders.
Relapse was diagnosed on the basis of clinical increase in palpable disease, and was confirmed whenever possible with repeat lymph node and bone marrow biopsies. good partial remission) having survived significantly longer than nonresponders (P = 0001) (fig 6) .
STATISTICS
None of the other factors we analysed were shown to influence survival. The longest follow-up is only 54 months, however, and since the predicted median survival of such patients is around four years this is clearly only a preliminary analysis.
Discussion
We must conclude that neither of our regimens is satisfactory for advanced non-Hodgkin's lymphoma of presumed good 
Introduction
There have been many reports of patients with coeliac disease and a coexistent disorder of known or suspected immunological aetiology.
I -7It has been suggested that such disorders are common as a result of either circulating immune complexes originating in the damaged small intestinel or the passage of antigens across the damaged intestine.7 Furthermore, Scott and Losowskyl thought that some immunological disorders in patients with coeliac disease might improve with a gluten-free diet. No supporting evidence for the suggestion was obtained from either individual patients or relatively small series of patients with coeliac disease, however, and the effect of a gluten-free diet on the progress of these associated conditions has not been reported. We describe the various immunological disorders found in a large series of patients with coeliac disease and examine the relation of a gluten-free diet to the time of presentation and course of the disorders.
Patients and methods
During 1958-77, 314 adults with coeliac disease confirmed by jejunal biopsy11 were followed up in this unit under the care of one of us (WTC). Fifty-four patients with coeliac disease seen before 1958 were excluded because either jejunal biopsy had not been carried out or their notes were inadequate for analysis. Of the 314 patients, 177 were women and 137 men; 28 of the women and 35 of the men died during the study.
Information about diseases of possible autoimmune or atopic aetiology was verified with the patients when possible and by review of notes on patients who had died or were seen only yearly. Aphthous ulceration and dermatitis herpetiformis-disorders with possible immunological aetiology related to gluten-were not included because of their known association with coeliac disease.9 10 
Results
IMMUNOLOGICAL DISEASE
We found 75 immunological disorders in 63 (20%') of the 314 patients (see table) . Of the 177 women, 34 (19 %) had 41 immunological diseases, and of the 137 men, 29 (21 %) had 34 diseases. Four women and five men had two immunological disorders each, and one woman had four coexistent disorders. In patients with autoimmune disorders the mean age at diagnosis of coeliac disease was 46 years, and in those with atopy it was 39 years. The mean age at onset of the autoimmune disorders was 38 years, but that of the atopic disorders could not be established.
Autoimmune disorders
Altogether, 52 autoimmune disorders were seen in 45 patients (14 %); 28 were seen in 23 of the women (13 %), and 24 in 22 of the men (16%). The most common disorder was diabetes mellitus. Ten patients had insulin-dependent diabetes, and four (three women and one man) had maturity-onset diabetes controlled by diet and oral hypoglycaemic agents. Eleven patients had thyroid disorders: four had thyrotoxicosis, of whom three (two women, one man) had Graves's disease and one man had a toxic adenoma; and seven (four women, three men) had myxoedema, of whom two had histologically proved Hashimoto's thyroiditis, one with a coexistent reticulum cell sarcoma of the thyroid.
